Peptide Library

In clinical trials

Skin & aging

LTX-315

Evidence

Clinical trials

Class

Oncolytic host-defense peptide

KEY TAKEAWAY

LTX-315 is a short synthetic peptide modeled on lactoferricin, a natural antimicrobial peptide. It was designed to be injected directly into tumors. LTX-315 is not FDA-approved and has only been tested in early-phase clinical trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Oncolytic host-defense peptide

Being studied for

Studied as an injection into solid tumors, alone and with immunotherapy

Key fact

LTX-315 is not FDA-approved and has only been tested in early-phase clinical trials.

Route

Injected directly into tumors in trials

Evidence strength

Clinical trials

What it is

What it is

LTX-315 is a short synthetic peptide modeled on lactoferricin, a natural antimicrobial peptide. It was designed to be injected directly into tumors.

How it works

How it works

It disrupts the membranes of cancer cells, causing them to burst and release tumor antigens that can prime the immune system.

Regulatory status

Regulatory status

LTX-315 is not FDA-approved and has only been tested in early-phase clinical trials.

What it is used for

What it is used for

Studied as an injection into solid tumors, alone and with immunotherapy.

Side effects and risks

Side effects and risks

Early trials reported injection-site reactions and other effects. Safety is still being evaluated.

Citations

Citations

LTX-315: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo